{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:33:25Z","timestamp":1791758005334,"version":"4.3.4"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1097\/ftd.0000000000000291","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T11:07:48Z","timestamp":1456398468000},"page":"371-378","source":"Crossref","is-referenced-by-count":28,"title":["Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data"],"prefix":"10.1097","volume":"38","author":[{"given":"Satoko","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Hashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1981.tb04327.x","article-title":"Monotherapy or polytherapy for epilepsy?","volume":"22","author":"Reynolds","year":"1981","journal-title":"Epilepsia"},{"key":"R2-14-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2003.09.007","article-title":"Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial","volume":"57","author":"Beghi","year":"2003","journal-title":"Epilepsy Res"},{"key":"R3-14-20210129","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neuropharm.2007.11.021","article-title":"SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy","volume":"54","author":"Kaminski","year":"2008","journal-title":"Neuropharmacology"},{"key":"R4-14-20210129","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5-14-20210129","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.clinthera.2010.09.001","article-title":"Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: open-label, single-dose, randomized, four-way crossover study in healthy male volunteers","volume":"32","author":"Stockis","year":"2010","journal-title":"Clin Ther"},{"key":"R6-14-20210129","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00228-003-0655-6","article-title":"Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers","volume":"59","author":"Strolin Benedetti","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-14-20210129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy","volume":"353","author":"Klitgaard","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"R8-14-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1528-1157.2003.25302.x","article-title":"Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid","volume":"44","author":"Coupez","year":"2003","journal-title":"Epilepsia"},{"key":"R9-14-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R10-14-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"R11-14-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2133\/dmpk.DMPK-13-RG-045","article-title":"Development of an integrated population pharmacokinetic model for oral levetiracetam in populations of various ages and ethnicities","volume":"29","author":"Toublanc","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"R12-14-20210129","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/j.1528-1167.2008.01974.x","article-title":"Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy","volume":"50","author":"Chhun","year":"2009","journal-title":"Epilepsia"},{"key":"R13-14-20210129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00003088-200847050-00004","article-title":"Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations","volume":"47","author":"Toublanc","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R14-14-20210129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/00003088-200746060-00004","article-title":"Population pharmacokinetics of levetiracetam in Japanese and Western adults","volume":"46","author":"Pigeolet","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R15-14-20210129","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R16-14-20210129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"key":"R17-14-20210129","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/bmc.2726","article-title":"Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring","volume":"26","author":"Shibata","year":"2012","journal-title":"Biomed Chromatogr"},{"key":"R18-14-20210129","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J Pharm Sci"},{"key":"R19-14-20210129","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40261-014-0237-7","article-title":"Levetiracetam pharmacokinetics in Japanese subjects with renal impairment","volume":"34","author":"Yamamoto","year":"2014","journal-title":"Clin Drug Investig"},{"key":"R20-14-20210129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1248\/bpb.17.323","article-title":"Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients","volume":"17","author":"Hashimoto","year":"1994","journal-title":"Biol Pharm Bull"},{"key":"R21-14-20210129","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1528-1157.2001.0420s4040.x","article-title":"Use of levetiracetam in special populations","volume":"42","author":"French","year":"2001","journal-title":"Epilepsia"},{"key":"R22-14-20210129","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"R23-14-20210129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"A general model for the origin of allometric scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science"},{"key":"R24-14-20210129","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.neuropharm.2008.08.032","article-title":"Several major antiepileptic drugs are substrates for human P-glycoprotein","volume":"55","author":"Luna-Tortos","year":"2008","journal-title":"Neuropharmacology"},{"key":"R25-14-20210129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuropharm.2006.07.038","article-title":"Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein","volume":"52","author":"Baltes","year":"2007","journal-title":"Neuropharmacology"},{"key":"R26-14-20210129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2013.03.049","article-title":"Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models","volume":"710","author":"Nakanishi","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"R27-14-20210129","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eplepsyres.2010.12.013","article-title":"Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with (11)C-desmethylloperamide","volume":"94","author":"Moerman","year":"2011","journal-title":"Epilepsy Res"},{"key":"R28-14-20210129","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R29-14-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eplepsyres.2011.01.007","article-title":"Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy","volume":"94","author":"Freitas-Lima","year":"2011","journal-title":"Epilepsy Res"},{"key":"R30-14-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pediatrneurol.2010.05.008","article-title":"Age and comedications influence levetiracetam pharmacokinetics in children","volume":"43","author":"Dahlin","year":"2010","journal-title":"Pediatr Neurol"},{"key":"R31-14-20210129","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2007.01043.x","article-title":"Effect of age and comedication on levetiracetam pharmacokinetics and tolerability","volume":"48","author":"Hirsch","year":"2007","journal-title":"Epilepsia"},{"key":"R32-14-20210129","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-200408000-00006","article-title":"Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs","volume":"26","author":"Contin","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R33-14-20210129","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.eplepsyres.2011.08.020","article-title":"Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy","volume":"98","author":"Contin","year":"2012","journal-title":"Epilepsy Res"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T04:05:32Z","timestamp":1654401932000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201606000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000291","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}